Gene-editing therapy Lyfgenia and CRISPR therapy Casgevy bring hope for sickle cell anemia patients but high costs pose challenges
FDA-approved Lyfgenia and CRISPR gene editing therapy Casgevy are effective against sickle cell disease, but the high price poses a challenge.
Source: abc7.com